DSIP
L-tryptophyl-L-alanyl-glycyl-glycyl-L-aspartyl-L-alanyl-L-seryl-glycyl-L-glutamic acid
DSIP is a naturally occurring nonapeptide identified in 1977 from rabbit cerebral venous blood, comprising nine amino acids in the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. This linear, hydrophilic peptide maintains its endogenous structure without synthetic modifications, making it ideal for sleep regulation research, stress response modulation, and central nervous system function studies in controlled experimental settings.
Clinical Benefits
Mechanism of Action
DSIP likely enhances GABAergic inhibition or suppresses glutamatergic activity in CNS models, promoting delta sleep, and reduces CRH release, modulating HPA responses. The peptide appears to interact with GABA_A receptors to facilitate inhibitory neurotransmission, while simultaneously downregulating corticotropin-releasing hormone (CRH) secretion from the hypothalamus, leading to reduced cortisol production and stress response. Though the exact receptor remains unidentified, its effects suggest interaction with multiple neuromodulatory pathways including GABAergic, glutamatergic, and hypothalamic-pituitary-adrenal systems.
Proven Results
Medical Disclaimer
DSIP is an investigational research compound not approved by the FDA for human therapeutic use. This information is for educational purposes only and should not be construed as medical advice. Any use should occur only under medical supervision in approved research settings.